Update to FY21 revenue guidance

RNS Number : 8020X
Oxford Nanopore Technologies plc
07 January 2022
 

ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU NO. 596/2014) WHICH FORMS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

 

7 January 2022

Oxford Nanopore Technologies plc

Update to FY21 revenue guidance

 

Oxford Nanopore Technologies plc ("the Group"), the company behind a new generation of nanopore-based sensing technology, is today providing an update to revenue guidance for the fiscal year ended 31 December 2021 ("FY21").

The Group expects to report core Life Science Research Tools ("LSRT") above £120 million, compared to LSRT revenue of £65.5 million in FY20, representing annual growth in excess of 83%.  Previous guidance for LSRT revenue in FY21 was £105-111 million.

The Group expects to report total revenue above £126 million, compared to total revenue of £113.9 million in FY20.

All other prior guidance remains unchanged.

The Group expects to report full results for FY21 in the second half of March 2022.

 

For further information please contact:

Oxford Nanopore Technologies plc

Investors:    ir@nanoporetech.com

Media:    media@nanoporetech.com

Tulchan Group (communications adviser to the Company)

Tom Murray, Olivia Peters, Deborah Roney

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@tulchangroup.com

The person responsible for arranging the release of this announcement on behalf of the Company is Hannah Coote, Company Secretary of Oxford Nanopore Technologies plc.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDUBOARUOUARAR
UK 100

Latest directors dealings